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Discovery. 1:126, 2004; Exp Hematol. 32:470, 2004; Exp Hematol.
32:300, 2004; Stem Cells. In press). In this ﬁrst phase I clinical trial
of CTCE-0214, the safety, tolerability, pharmacokinetic proﬁle,
and the pharmacodynamic effects of single subcutaneous doses of
CTCE-0214 given to healthy subjects were studied. The random-
ized, double-blinded, placebo-controlled dose-escalation trial en-
rolled 24 subjects in 6 dose-escalation groups. Four healthy human
subjects in each cohort received either CTCE-0214 or Placebo,
randomized in a 3:1 ratio. The doses of CTCE-0214 were 0.2
mg/kg, 0.5 mg/kg, 0.8 mg/kg, 1.5 mg/kg, 2.0 mg/kg, and 3.0
mg/kg. CTCE-0214 was shown to be safe with no serious adverse
events reported. The most common drug related adverse events
were injection site pain and erythema, which were transient and
resolved without intervention. The severity of injection site pain
appeared to be associated with the overall quantity of study drug
administered. Moderate or severe pain was reported only at 80 mg
or greater of CTCE-0214 per syringe. Dilution across more than
one syringe appeared to effectively reduce injection site pain.
Pharmacokinetic analysis of CTCE-0214 plasma concentrations
showed that Tmax was reached at 0.25 hours post-administration
for all CTCE-0214 treated cohorts. The apparent terminal elim-
ination half-life (t1/2) values were estimated to be 0.41 to 0.32
hours. CTCE-0214 administration was associated with signiﬁcant
dose-dependent increases in total white blood cell and neutrophil
counts in treated subjects, peaking at around 6 hours post-injec-
tion. In the 3.0 mg/kg arm, the mean difference in neutrophil
count from baseline was more than three times that of the Placebo
arm. The same trend was apparent in the 2.0 and 1.5 mg/kg arms.
These results suggest that SDF-1 agonists may potentially be used
in patients with low neutrophil count receiving chemotherapy with
or without the use of G-CSF. The potential for CTCE-0214 to
mobilize neutrophils and other blood cells merits serious consid-
eration.
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Dyskeratosis congenita (DC) is an inherited multisystem disorder
of premature aging characterized by early bone marrow (BM)
failure. This disease is due to telomerase defects resulting in telo-
mere shortening and premature senescence of various somatic
cells, particularly those from highly proliferative tissues. Telomer-
ase plays an important though not fully understood role in hema-
topoiesis. We have recently identiﬁed a three-generation kindred
with autosomal dominant DC with affected individuals having a
single gene deletion of the RNA component of telomerase,
hTERC, and recent third generation patients are displaying signs
of BM dysfunction at an earlier age than their affected parents. To
explain these ﬁndings, we hypothesize that early BM failure in DC
may be due to a proliferative/differentiative defect in hematopoi-
etic stem cells (HSC) as a consequence of telomere shortening.
Five patients (age 11–50) from 2 successive generations have thus
far been enrolled on a study that allows collection of HSC by
leukopheresis. All patients had clinical and laboratory features of
DC, including signiﬁcant BM hypocellularity (10–30%). The per-
centage of CD34 cells in the G-CSF primed leukopheresis prod-
uct was signiﬁcantly lower in DC subjects (0.05–0.24%) compared
to controls (0.7–1.2%). Extensive immunophenotyping of HSC
revealed a higher percentage of CD33/CD34 cells in DC
subjects (60–97%) relative to controls (9–28%). HSC function was
examined in vitro by a clonogenic progenitor cell assay, assessing
percent, number, and morphology of colony forming units (CFU).
Of note, 2/5 DC subjects (both third generation) had a markedly
reduced number of CFU, and percentage of CFU-GM and CFU-
GEMM were decreased in 4/5 DC subjects relative to controls. To
assess DC HSC function in vivo, CD34 HSC from 2 different
DC subjects and age-matched controls were injected into suble-
thally irradiated NOD-SCID mice. None of the mice injected with
DC HSC showed evidence of human hematopoiesis at up to 20
weeks post injection, while animals receiving control HSC had
evidence of human hematopoiesis by 6 weeks. In conclusion, DC is
an excellent human model to assess the role of telomerase and
telomere shortening in hematopoiesis. Importantly, there appears
to be a correlation of the DC clinical phenotype and DC HSC
function with telomere length. Further studies are needed to de-
termine whether the aberrant function of DC HSC can be rescued
by a gene-transfer approach.
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Hemopoietic stem cells (HSCs) are rare cells of the hemopoietic
system with the ability to self-renew and differentiate into mature
blood cells. The application of HSC transplantation as a curative
intervention can be limited by the lack of a suitable donor or the
suboptimal collection of HSCs. Umbilical cord blood (UCB) cells
have potential as a readily available alternate source of HSCs but at
present have limited utility in adult recipients because the relatively
low numbers of HSCs can lead to delayed hemopoietic reconsti-
tution. At present, there exists no therapeutic intervention that
allows for the in vivo expansion of transplanted HSCs. We exam-
ined the effects of inhibiting glycogen synthase kinase-3 (GSK-3),
a constitutively active serine/threonine kinase, on the regulation of
the human HSC pool. Primitive lineage-depleted (Lin-) neonatal
UCB cells or adult G-CSF mobilized peripheral blood (M-PB)
cells were intravenously injected into sublethally irradiated NOD/
SCID mice. The mice were then treated with either 30 mg/kg of
a GSK-3 inhibitor or with vehicle twice per week for the duration
of the 5 to 6 week transplant period. NOD/SCID recipients
treated with the GSK-3 inhibitor demonstrated an increased fre-
quency and total number of primitive human HSCs (CD45
CD34) after transplantation of UCB-derived HSCs compared to
vehicle-treated controls. The mean number of HSCs in the bone
marrow were 12791  2892 versus 62374  15533, respectively,
(mean  SEM; P  .02; N  4 mice/group). To further charac-
terize the effect of GSK-3 inhibition on human HSC repopulating
capacity, sorted CD45 human hematopoietic cells from the re-
constituted mice were plated in a functional clonogenic in vitro
assay. Hemopoietic cells derived from recipients reconstituted with
UCB or M-PB-HSCs and treated with GSK-3 inhibitor generated
greater numbers of HSC-colony forming units (HSC-CFU) than
untreated controls (mean  SEM: 2121  526 versus 1021  356;
respectively. P .038, N 7). The developmental potential of the
HSC-CFU to form mature colonies of various subtypes (erythroid,
granulocyte, macrophage, and granulocyte-macrophage) was not
altered by the treatment. Our results demonstrate that GSK-3 can
modulate HSC activity in vivo and suggest that administration of
GSK-3 inhibitor may provide a clinical means to directly enhance
the repopulating capacity of transplanted HSCs.
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Multipotent Adult Progenitor cells (MAPC) are nonhematopoi-
etic stem cells, present within the bone marrow that can be grown
extensively and can be induced to generate cells with phenotypic
characteristics and gene proﬁle of cells derived from endoderm,
ectoderm and mesoderm. The capacity to differentiate into these
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